Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
about
Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: protocol for a systematic review and individual patient data network meta-analysisUse of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study.Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.Third degree atrioventricular block associated with treatment with rivastigmine transdermal patchCardiovascular effects of drugs used to treat Alzheimer's disease.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Association between dentures and the rate of falls in dementiaLong-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition.The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, CanadaCardiorespiratory response to exercise testing in individuals with Alzheimer's disease.Somatic comorbidities and Alzheimer's disease treatment.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.RGS Proteins in Heart: Brakes on the Vagus.Energy expenditure in frontotemporal dementia: a behavioural and imaging study.Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.Could cholinesterase inhibitors be harmful over the long term?European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients
P2860
Q26997299-BA1E1C2E-B524-40DB-9C07-65E3FCBD2884Q28080099-CBB4F920-2C7F-4162-B8C5-2F86ABC345B5Q33161031-76500423-DD51-4586-AF3D-006E10857BC2Q33161551-9805689E-524A-4311-8578-3F50D8FA3C14Q33162691-1F889186-95FC-4471-8B6A-B2E19AF4237BQ33164224-CB68EF4E-DB3B-462A-947D-412A902B08AAQ33165693-EE878364-DB49-4D49-9190-5947D951EFFCQ33165801-2D2ABE6F-283F-4809-AAC2-D0044843A740Q33817743-A3CBAD15-1945-4773-BFD5-05A65D2D4068Q35006354-239DA223-FE26-4836-BC61-A1E2E5324BC7Q35107345-C2C0277F-DAED-42EF-B1FC-1CECFEB6E239Q35568937-6B65CA79-0D39-4945-B505-A1DA4CB9FBD8Q35589793-31969963-4D1B-4389-B592-8034E8B851ACQ37199794-F421C05F-0121-4D83-9DDE-76EBEDB9944DQ38906350-A8AD8FB0-EFB2-4E2E-84B9-3F97E81CB89EQ38920515-8146FCA2-604B-45F4-B77F-01A5C1F459A7Q39415447-CF5CD224-8EAC-4406-8BD9-95FAA9BEE036Q41875965-6C399567-0649-487F-9522-634318C49369Q47136369-29E3B78C-697A-42D7-A976-38E956C9D225Q47955004-517DC653-F95B-4420-81A1-6F9B683F99C6Q48167336-899E591C-833D-4D97-8784-007FD6AFEC37Q48254545-25C74A4D-50AF-498C-BECD-D22D417B0FF2Q53324826-6F128261-FD6A-415D-9C06-2389F7D17F58Q55208569-976C8B37-1FE9-46A3-8221-EE4AB757B4DDQ55231435-D1317133-75C7-4480-842A-08138DD36306Q57244256-B78D33CD-14EA-4CA1-A249-8E6DB4D5D6D3
P2860
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cholinesterase inhibitors and ...... new England healthcare system.
@ast
Cholinesterase inhibitors and ...... new England healthcare system.
@en
type
label
Cholinesterase inhibitors and ...... new England healthcare system.
@ast
Cholinesterase inhibitors and ...... new England healthcare system.
@en
prefLabel
Cholinesterase inhibitors and ...... new England healthcare system.
@ast
Cholinesterase inhibitors and ...... new England healthcare system.
@en
P2093
P1476
Cholinesterase inhibitors and ...... new England healthcare system.
@en
P2093
Elizabeth V Lawler
Michael D Cantor
Rohini K Hernandez
Wildon Farwell
P2860
P304
P356
10.1111/J.1532-5415.2009.02488.X
P407
P577
2009-09-28T00:00:00Z